The global antiplatelet market was valued at $3.8 billion in 2022, and is projected to reach $5.8 billion by 2032, growing at a CAGR of 4.2% from 2023 to 2032.
Antiplatelet agents, also known as antiplatelet drugs, are a class of medications that work to prevent the formation of blood clots by inhibiting the activation and aggregation of platelets, which are small blood cells responsible for clot formation. These medications are commonly used in the prevention and management of cardiovascular diseases, such as heart attacks and strokes.
Platelets play a crucial role in hemostasis, the process that stops bleeding after an injury. When a blood vessel is damaged, platelets adhere to the site and aggregate together, forming a clot that helps seal the injury. However, in certain medical conditions, such as atherosclerosis or irregular heart rhythms, blood clots can form within blood vessels inappropriately, leading to blockages that may result in heart attacks or strokes. Antiplatelet drugs work by interfering with different steps in the platelet activation and aggregation process. Some commonly used antiplatelet medications include aspirin, clopidogrel, ticagrelor, and prasugrel. These drugs inhibit platelet activation by blocking specific receptors or enzymes involved in the clotting pathway.
The antiplatelets market is driven by factors such as the increase in prevalence of cardiovascular diseases, such as heart attacks and stroke that drives the demand for antiplatelet drugs as a preventive and treatment measure thereby propelling the market growth. For instance, according to the American Association, the prevalence of stroke in 2020 was 89.1 million people across the globe. In addition, the ischemic stroke was 68.2 million, that of intracerebral hemorrhage was 18.9 million, and that of subarachnoid hemorrhage was 8.1 million across the globe. Thus, rise in the cases of cardiovascular diseases drives the demand for antiplatelet drugs and propels the market growth.
In addition, ongoing R&D efforts in the field of antiplatelet drugs lead to the discovery of novel agents with enhanced efficacy and safety profiles. The introduction of new and improved drugs stimulates market growth and attracts investment in the sector. For instance, Lee's Pharmaceutical Limited is conducting a phase 1 clinical trial to investigate the tolerability, safety, and pharmacokinetics of Anfibatate.
Furthermore, percutaneous coronary intervention (PCI), commonly known as angioplasty, is a surgical procedure used to treat coronary artery disease. Antiplatelet medications play a crucial role in PCI procedures, both during and after the intervention. Thus, the surge in usage of antiplatelet drugs in percutaneous coronary intervention contributes to the expansion of the antiplatelet market.
The antiplatelet market is segmented into drug class, route of administration, distribution channel, and region. As per drug class, the market is segregated into adenosine diphosphate (ADP) receptor inhibitors, irreversible inhibitors cyclooxygenase, and others. By route of administration, it is categorized into oral and injectable. Depending on distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the antiplatelet market are AstraZeneca plc, Bayer AG, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Cipla Ltd., Otsuka Pharmaceutical Co., Ltd., Lupin, Sanofi S.A., Daiichi Sankyo Company Limited, and Chiesi Farmaceutici S.p.A. Key players operating in the market have adopted product approval as their key strategies to expand their product portfolio.
Antiplatelet agents, also known as antiplatelet drugs, are a class of medications that work to prevent the formation of blood clots by inhibiting the activation and aggregation of platelets, which are small blood cells responsible for clot formation. These medications are commonly used in the prevention and management of cardiovascular diseases, such as heart attacks and strokes.
Platelets play a crucial role in hemostasis, the process that stops bleeding after an injury. When a blood vessel is damaged, platelets adhere to the site and aggregate together, forming a clot that helps seal the injury. However, in certain medical conditions, such as atherosclerosis or irregular heart rhythms, blood clots can form within blood vessels inappropriately, leading to blockages that may result in heart attacks or strokes. Antiplatelet drugs work by interfering with different steps in the platelet activation and aggregation process. Some commonly used antiplatelet medications include aspirin, clopidogrel, ticagrelor, and prasugrel. These drugs inhibit platelet activation by blocking specific receptors or enzymes involved in the clotting pathway.
The antiplatelets market is driven by factors such as the increase in prevalence of cardiovascular diseases, such as heart attacks and stroke that drives the demand for antiplatelet drugs as a preventive and treatment measure thereby propelling the market growth. For instance, according to the American Association, the prevalence of stroke in 2020 was 89.1 million people across the globe. In addition, the ischemic stroke was 68.2 million, that of intracerebral hemorrhage was 18.9 million, and that of subarachnoid hemorrhage was 8.1 million across the globe. Thus, rise in the cases of cardiovascular diseases drives the demand for antiplatelet drugs and propels the market growth.
In addition, ongoing R&D efforts in the field of antiplatelet drugs lead to the discovery of novel agents with enhanced efficacy and safety profiles. The introduction of new and improved drugs stimulates market growth and attracts investment in the sector. For instance, Lee's Pharmaceutical Limited is conducting a phase 1 clinical trial to investigate the tolerability, safety, and pharmacokinetics of Anfibatate.
Furthermore, percutaneous coronary intervention (PCI), commonly known as angioplasty, is a surgical procedure used to treat coronary artery disease. Antiplatelet medications play a crucial role in PCI procedures, both during and after the intervention. Thus, the surge in usage of antiplatelet drugs in percutaneous coronary intervention contributes to the expansion of the antiplatelet market.
The antiplatelet market is segmented into drug class, route of administration, distribution channel, and region. As per drug class, the market is segregated into adenosine diphosphate (ADP) receptor inhibitors, irreversible inhibitors cyclooxygenase, and others. By route of administration, it is categorized into oral and injectable. Depending on distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the antiplatelet market are AstraZeneca plc, Bayer AG, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Cipla Ltd., Otsuka Pharmaceutical Co., Ltd., Lupin, Sanofi S.A., Daiichi Sankyo Company Limited, and Chiesi Farmaceutici S.p.A. Key players operating in the market have adopted product approval as their key strategies to expand their product portfolio.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antiplatelet market analysis from 2022 to 2032 to identify the prevailing antiplatelet market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the antiplatelet market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global antiplatelet market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly update (only available with the purchase of an enterprise license)
- 5 additional company profiles of your choice, pre- or post-purchase, as a free update.
- Free updated version (once released) with the purchase of a 1-5 or enterprise user license.
- 16 analyst hours of support (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% free customization (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
- Free data pack (Excel version) with the purchase of a 1-5 or enterprise user license.
- Free report update, if the report is 6-12 months old or older.
- 24-hour priority response
- Free industry updates and white papers.
Key Market Segments
By Drug Class
- Adenosine diphosphate (ADP) receptor inhibitors
- Irreversible inhibitors cyclooxygenase
- Others
By Route of Administration
- Oral
- Injectable
By Distribution Channel
- Hospital pharmacies
- Drug store and retail pharmacies
- Online providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Sanofi S.A.
- Glenmark Pharmaceuticals Limited
- Cipla Ltd.
- Lupin
- Bayer AG
- Otsuka Pharmaceutical Co., Ltd.
- Daiichi Sankyo Company Limited
- Chiesi Farmaceutici S.p.A.
- AstraZeneca plc
- Eli Lilly and Company.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: ANTIPLATELET MARKET, BY DRUG CLASS
CHAPTER 5: ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION
CHAPTER 6: ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: ANTIPLATELET MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to this report, the antiplatelet market was valued at $3.8 billion in 2022, and is estimated to reach $5.8 billion by 2032, growing at a CAGR of 4.2% from 2023 to 2032.The Antiplatelet Market is likely to experience a significant growth rate of 4.2% from 2023-2032 owing to increase in demand for antiplatelets drugs from pharmaceutical sector
Antiplatelet drugs refer to the medications that are specifically designed to prevent blood clot formation by inhibiting platelet aggregation. Antiplatelet drugs work by interfering with the clotting process in the blood and reducing the risk of thrombotic events such as heart attacks, strokes, and peripheral arterial disease. They work to make platelets less sticky and thereby help prevent blood clots from forming in arteries. Examples of antiplatelets drugs include Aspirin, Clopidogrel (Plavix), Prasugrel (Effient), and Ticagrelor (Brilinta).
Key factors driving the growth of the antiplatelet market include the rise in prevalence of cardiovascular diseases and rise in the geriatric population. Older adults often require long-term treatment with antiplatelet drugs to manage their conditions and reduce the risk of adverse cardiovascular events which is expected to support the market growth. Cardiovascular diseases encompass a range of conditions affecting the heart and blood vessels, including coronary artery disease, myocardial infarction (heart attack), ischemic stroke, peripheral arterial disease, and others.
In addition, growing awareness about early diagnosis of cardiovascular diseases and their management in developing countries led to the increase in demand for the antiplatelet drugs that propels the market growth. For instance, in September 2021, the European Society of Cardiology (ESC) and fourteen other European organizations launched the European Alliance for Cardiovascular Health (EACH), which aims to raise awareness about the growing burden of cardiovascular disease and to develop a comprehensive plan specifically targeting cardiovascular disease in the Europe region. Furthermore, ongoing research and development efforts aim to improve the efficacy, safety, and specificity of antiplatelet medications are anticipated to propel the market growth.
Antiplatelet drugs play a crucial role in reducing the risk of clot formation and preventing complications associated with cardiovascular diseases. The growing prevalence of cardiovascular diseases is attributed to various factors, such as sedentary lifestyles, unhealthy dietary habits, obesity, diabetes, smoking, and an aging population. Thus, the use of antiplatelet medications during and after angioplasty and stent procedures significantly drives the antiplatelet market.
The market also offers growth opportunities to the key players in the market. Developing countries represent potential for antiplatelets market, owing to surge in demand for better healthcare facilities and surge in need for cardiovascular medications. Countries such as India and China have the largest patient pool in the world and are showing great potential with growing healthcare infrastructure which provide the lucrative opportunity to the market growth. In addition, the increase in incidence of cardiovascular diseases, such as heart attacks, strokes, and peripheral artery disease, provides a significant opportunity for the antiplatelet market. As the global burden of cardiovascular diseases continues to grow, there is a higher demand for preventive and therapeutic measures such as the use of antiplatelet drugs.
The antiplatelet market is segmented into m drug class, route of administration, distribution channel and region. On the basis of drug class, the market is categorized into adenosine diphosphate (ADP) receptor inhibitors, irreversible inhibitors cyclooxygenase, and others. On the basis of route of administration, it is categorized into oral and injectable. On the basis of distribution channel, it is segregated into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, it is analyzed across North America (the U. S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific ((Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include AstraZeneca plc, Bayer AG, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Cipla Ltd., Otsuka Pharmaceutical Co., Ltd., Lupin, Sanofi S. A., Daiichi Sankyo Company Limited, and Chiesi Farmaceutici S. p.A. The players in the market have been actively engaged in the adoption various strategies such as a product approval to remain competitive and gain advantage over the competitors in the market. For instance, in November 2020, AstraZeneca received the approval of Brilinta (ticagrelor) in the U. S. to reduce the risk of stroke, in patients with acute ischemic stroke or high-risk transient ischaemic attack (TIA).
Key Market Insights
By drug class, the adenosine diphosphate (ADP) receptor inhibitors segment was the largest revenue contributor to the market and is estimated to reach $4.13 billion by 2032, with a highest CAGR of 4.4%.By route of administration, the oral segment dominated the global market with a highest CAGR of 4.2% during the forecast period.
Based on distribution channel, the drug store and retail pharmacies segment was the largest revenue contributor to the market. However, the online providers segment is anticipated to grow at the highest CAGR of 4.3% during the forecast period.
Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Sanofi S.A.
- Glenmark Pharmaceuticals Limited
- Cipla Ltd.
- Lupin
- Bayer AG
- Otsuka Pharmaceutical Co., Ltd.
- Daiichi Sankyo Company Limited
- Chiesi Farmaceutici S.p.A.
- AstraZeneca plc
- Eli Lilly and Company.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
